Squarepoint
NTLA icon

Squarepoint’s Intellia Therapeutics NTLA Stock Holding History

Squarepoint’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,800
Closed -$376K – 4690
2025
Q3 		$376K Buy
+21,800
New +$268K ﹤0.01% 3487

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Squarepoint's NTLA Position: Q1 2026 in Review

Squarepoint increased its Intellia Therapeutics (NTLA) stake by 47% in Q1 2026, buying an estimated $857K and bringing the position to 209,983 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1972.

Squarepoint first reported a position in NTLA in Q4 2017 and has held it in 24 quarters since. The position peaked at $13.1M in Q3 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Squarepoint held 209,983 shares of Intellia Therapeutics worth $2.69M as of Q1 2026.
  • Squarepoint bought 67,248 Intellia Therapeutics shares in Q1 2026, an estimated $857K.
  • Intellia Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1972 holding.
  • Squarepoint first reported a position in Intellia Therapeutics in Q4 2017 and has held it in 24 quarters since.
  • Squarepoint's Intellia Therapeutics position peaked at $13.1M in Q3 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.